Evidence map›Paper›PMID 33549576›Full record

ArticleExperimental cell research2021

Noonan syndrome patient-specific induced cardiomyocyte model carrying SOS1 gene variant c.1654A>G.

Narasimman Gurusamy, Sheeja Rajasingh, Vinoth Sigamani, Reshma Rajasingh, Dona Greta Isai, Andras Czirok, Douglas Bittel, Johnson Rajasingh

Open access · greenAbstract read
In one paragraph

Article in Experimental cell research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Biomarker Landscape in RASopathies.International journal of molecular sciences · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Current genomics · 2021
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Narasimman GurusamyDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, USA.
Sheeja RajasinghDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, USA.
Vinoth SigamaniDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, USA.
Reshma RajasinghDartmouth College, Hanover, NH, USA.
Dona Greta IsaiDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS, USA.
Andras CzirokDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS, USA.
Douglas BittelChildren's Mercy Hospital, Kansas City, MO, USA.
Johnson RajasinghDepartment of Bioscience Research, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Medicine-Cardiology, University of Tennessee Health Science Center, Memphis, TN, USA; Department of Microbiology, Immunology & Biochemistry, University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: rjohn186@uthsc.edu.
University of Tennessee Health Science Center · USUniversity of Kansas Medical Center · USChildren's Mercy Hospital · USDartmouth College · US

Funding

scaRNA Modified Induced Pluripotent Stem Cell-Derived Cardiomyocytes or Exosomes Therapy for Chronic Ischemic Cardiomyopathy PatientsR01HL141345 · NHLBI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI JOHNSON, RAJASINGH · 2019 to 2022
$1.5M
NHLBI NIH HHS R01 HL141345
6 · The paper itself

Abstract

Noonan syndrome (NS) is a dominant autosomal genetic disorder, associated with mutations in several genes that exhibit multisystem abnormal development including cardiac defects. NS associated with the Son of Sevenless homolog 1 (SOS1) gene mutation attributes to the development of cardiomyopathy and congenital heart defects. Since the treatment option for NS is very limited, an in vitro disease model with SOS1 gene mutation would be beneficial for exploring therapeutic possibilities for NS. We reprogrammed cardiac fibroblasts obtained from a NS patient and normal control skin fibroblasts (C-SF) into induced pluripotent stem cells (iPSCs). We identified NS-iPSCs carry a heterozygous single nucleotide variation in the SOS1 gene at the c.1654A > G. Furthermore, the control and NS-iPSCs were differentiated into induced cardiomyocytes (iCMCs), and the electron microscopic analysis showed that the sarcomeres of the NS-iCMCs were highly disorganized. FACS analysis showed that 47.5% of the NS-iCMCs co-expressed GATA4 and cardiac troponin T proteins, and the mRNA expression levels of many cardiac related genes, studied by qRT-PCR array, were significantly reduced when compared to the control C-iCMCs. We report for the first time that NS-iPSCs carry a single nucleotide variation in the SOS1 gene at the c.1654A>G were showing significantly reduced cardiac genes and proteins expression as well as structurally and functionally compromised when compared to C-iCMCs. These iPSCs and iCMCs can be used as a modeling platform to unravel the pathologic mechanisms and also the development of novel drug for the cardiomyopathy in patients with NS.

Indexed as

MutationCase-Control StudiesCells, CulturedHumansInduced Pluripotent Stem CellsMyocytes, CardiacNoonan SyndromeSOS1 ProteinSOS1 ProteinSOS1 protein, humanCardiomyopathyInduced cardiomyocytesInduced pluripotent stem cellsNoonan syndromeSOS1 gene

Identifiers

PMID33549576
PMCPMC8542457
OpenAlexW3128198768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.